Nymox’s Alzheimer test to be provided in UK by Lab21

AlzheimAlert is Nymox’s unique, proprietary product that provides physicians with a valuable tool for the diagnosis of Alzheimer’s disease (AD) by measuring levels of a brain protein in patients’ urine samples.

Lab21 provides technically advanced clinical testing services for the pharmaceutical industry and healthcare providers in the UK through its extensive, fully accredited laboratory facilities in Cambridge, England. Lab21’s current services include unique know-how in antiviral drug discovery plus a portfolio of cutting-edge molecular diagnostics, viral characterisation, pharmacogenetic tests, and patient profiling.

“This agreement will give physicians in the UK access to our AlzheimAlert testing technology,” said Brian Doyle, Nymox’s senior manager for worldwide sales and marketing. “With this agreement, the UK joins Spain, Greece, Italy and the Czech Republic as EU countries in which our AlzheimAlert product is now available.”

The AlzheimAlert test uses patented state-of-the-art technology to measure the level of a brain protein called neural thread protein (NTP) found in higher amounts in the urine of patients suffering from Alzheimer’s disease. The test provides valuable information for physicians in the often difficult task of Alzheimer’s disease diagnosis and is the only test of its kind.